- Home
- ORCL vs ABBV Comparison
ORCL vs ABBV Comparison
Compare ORCL & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORCL | ABBV |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.1B | 375.7B |
| IPO Year | 2005 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ORCL | ABBV |
|---|---|---|
| Price | $172.76 | $197.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 19 |
| Target Price | ★ $260.11 | $250.94 |
| AVG Volume (30 Days) | ★ 25.9M | 4.6M |
| Earning Date | 06-10-2026 | 04-29-2026 |
| Dividend Yield | 1.15% | ★ 3.48% |
| EPS Growth | ★ 16.98 | N/A |
| EPS | ★ 4.38 | 2.36 |
| Revenue | $57,399,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $19.50 | $11.87 |
| Revenue Next Year | $31.91 | $8.12 |
| P/E Ratio | ★ $39.62 | $84.38 |
| Revenue Growth | 8.38 | ★ 8.57 |
| 52 Week Low | $134.57 | $180.25 |
| 52 Week High | $345.72 | $244.81 |
Technical Indicators
Market Signals| Indicator | ORCL | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 33.00 |
| Support Level | $136.34 | $186.13 |
| Resistance Level | $229.66 | $234.00 |
| Average True Range (ATR) | 8.14 | 4.98 |
| MACD | 1.97 | -0.64 |
| Stochastic Oscillator | 70.20 | 8.16 |
Price Performance
Historical ComparisonAbout ORCL Oracle Corporation
Oracle provides enterprise applications and infrastructure offerings through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used by the world's largest companies for high-volume online transaction processing workloads. Besides databases, Oracle also sells enterprise resource planning platforms and cloud infrastructure that play an increasingly important role in large language model training and inferencing.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.